- Home
- FDMT vs DSGN Comparison
FDMT vs DSGN Comparison
Compare FDMT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDMT
- DSGN
- Stock Information
- Founded
- FDMT 2013
- DSGN 2017
- Country
- FDMT United States
- DSGN United States
- Employees
- FDMT N/A
- DSGN N/A
- Industry
- FDMT Biotechnology: Pharmaceutical Preparations
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- FDMT Health Care
- DSGN Health Care
- Exchange
- FDMT Nasdaq
- DSGN Nasdaq
- Market Cap
- FDMT 192.2M
- DSGN 208.9M
- IPO Year
- FDMT 2020
- DSGN 2021
- Fundamental
- Price
- FDMT $4.38
- DSGN $3.95
- Analyst Decision
- FDMT Buy
- DSGN Hold
- Analyst Count
- FDMT 10
- DSGN 1
- Target Price
- FDMT $32.33
- DSGN $4.00
- AVG Volume (30 Days)
- FDMT 410.7K
- DSGN 101.0K
- Earning Date
- FDMT 08-07-2025
- DSGN 08-04-2025
- Dividend Yield
- FDMT N/A
- DSGN N/A
- EPS Growth
- FDMT N/A
- DSGN N/A
- EPS
- FDMT N/A
- DSGN N/A
- Revenue
- FDMT $23,000.00
- DSGN N/A
- Revenue This Year
- FDMT $13,048.65
- DSGN N/A
- Revenue Next Year
- FDMT N/A
- DSGN N/A
- P/E Ratio
- FDMT N/A
- DSGN N/A
- Revenue Growth
- FDMT N/A
- DSGN N/A
- 52 Week Low
- FDMT $2.24
- DSGN $2.60
- 52 Week High
- FDMT $28.93
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- FDMT 56.61
- DSGN 55.03
- Support Level
- FDMT $4.23
- DSGN $3.52
- Resistance Level
- FDMT $4.50
- DSGN $4.21
- Average True Range (ATR)
- FDMT 0.26
- DSGN 0.28
- MACD
- FDMT 0.01
- DSGN 0.03
- Stochastic Oscillator
- FDMT 85.37
- DSGN 77.27
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.